Shire Corporate Education Session

Managing mineral and bone disorders in CKD patients receiving dialysis:
challenges, treatment and adherence

Chronic kidney disease-mineral and bone disorder (CKD-MBD) is a broad clinical syndrome associated with morbidity, decreased quality of life and increased cardiovascular mortality¹. In this session, the challenges that this complex disorder presents to patients and healthcare professionals will be assessed.

The Faculty will also share their knowledge and expertise on hyperphosphataemia and its management, with an emphasis on the issue of patient adherence. We are all aware of the difficulties patients face in dealing with their condition and taking medication, and delegates will hear the latest thinking on the psychology of non-adherence, which will illustrate the importance of understanding CKD-MBD from a patient’s perspective. Real-life experiences of the impact of CKD-MBD and its treatment will be shared through a series of patient case studies.

Programme

References
1. Moe S et al. Kidney Int 2006;69:1945-53.

Congress Hall, 7.9., 11:00

Genzyme Corporate Education Session

Bone and mineral disorders in CKD patients: the importance of phosphorus management

Disturbances of bone and mineral metabolism (including hyperphosphatemia and hyperparathyroidism) are a hallmark of chronic kidney disease (CKD). The inability to adequately remove phosphate in patients with impaired renal function, hypocalcemia, and altered vitamin D metabolism all contribute to the development of secondary (renal) hyperparathyroidism. The consequences include the development of accelerated arteriosclerosis and increased cardiovascular mortality in patients with renal failure. Strategies to reduce the cardiovascular disease burden in CKD patients aim at the reduction of phosphate load (diet, phosphate binders, dialysis therapy) and at the restoration of the disturbed vitamin D metabolism. Recent developments
on the field of pathophysiology as well as treatment will be discussed. Also an example will be given of an educational intervention to improve phosphate levels in dialysis patients. The optimum strategy for phosphate control relies on patient involvement and joint efforts of the entire clinical team.

Phosphorus as a cardiovascular risk factor in CKD: therapeutic implications
V. Brandenburg, Aachen, Germany

Phosphorus management in the clinic: a Swedish approach
E. Johnsson, Malmö, Sweden

Chairs: Georgia Thanasa & Deepa Kariyawasam

Congress Hall, 7.9., 14:00

Baxter Corporate Education Session

Bone and mineral disorders in CKD patients: the importance of phosphorus management

Join us for the Baxter Corporate Education Session at this year’s EDTNA/ERCA.
We anticipate a practical and informative event.
The session explores the challenging area of minimising infections for dialysis patients.

Does the way you start dialysis matter?
Dr Peter Rutherford MD, PhD, FRCP
Baxter

Challenges in PD
Speaker to be Confirmed

Challenges in HD
Speaker to be Confirmed

Therapy transfers: what are the risks?
Dr. Watske Smith MD, PhD.
AMC Amsterdam

Chairs: Zehra Aydin & Dragica M

Meeting Hall 1, 8.9., 11:00

Fresenius Medical Care Corporate Education Session

There is Always a Story Behind an Act of Caring: Ensuring Quality & Safety in Dialysis Care

Providing Dialysis Therapy Options: What can and should be removed?
Sudhir Bowry, Germany

Protecting the Patients and Yourself from Infection: It is in your hands!
João Fazendeiro, Portugal

Seeing, Reporting and Acting on all Symptoms and Mistakes: Clinical vigilance: avoiding clinical hazards!
Isabel Soley, Spain

Putting Theory into Clinical Practice: Are we really up-to-date?
Cathy Poole, United Kingdom

Improving the Patients Well-being: That should be our common commitment
Maria Teresa Parisotto, Italy

Chair: Jutta Balhorn

Congress Hall, 8.9., 14:00